NCT05374278View on ClinicalTrials.gov

First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

102

Participants

Timeline

Start Date

November 2, 2021

Primary Completion Date

April 3, 2027

Study Completion Date

May 31, 2027

Conditions

Alzheimer DiseaseFrontotemporal DementiaDementia

Interventions

DRUG

[18F]RP-115 PET/MRI or PET/CT and MRI

An I.V. bolus injection of up to 10 millicurie (mCi) \[18F\]RP-115 will be administered, followed by a PET/MRI scan or by a combination of PET/CT and MRI

Trial Locations (1)

94107

RECRUITING

China Basin, UCSF, San Francisco

All Listed Sponsors

collaborator

Rio pharmaceuticals Inc.

UNKNOWN

lead

David Wilson

OTHER